

[Home](#)

[Strategy](#)

[Team](#)

[Research](#)

[Annual Meeting](#)

[LP Link](#)

---

With a core investment team averaging 24 years of early-stage venture capital experience, Spur Capital brings diverse and rich insights to each of its funds-of-funds.

**Spur Capital has a successful history of building durable relationships with top-tier venture capital firms in early-stage technology and life science as well as uncovering up-and-coming firms. Limited partners are leading endowments, family offices, foundations, and institutional investors in the United States and Western Europe.**

## **our time-tested approach**

**IDENTIFYING AND PREDICTING SUCCESS IN EARLY-STAGE VENTURE CAPITAL**

Academic research has demonstrated the historical persistence of relative outperformance of venture capital investing. Given this documented characteristic and its own investment experience, Spur emphasizes firms with significant prior success. Each Spur fund has carried forward a core group of prior Funds' most successful relationships; concurrently Spur Capital evaluates potential new relationships that might "average up" the portfolio.

In the search for the next generation of top-tier venture firms, Spur pursues groups with unique talents and operating experience, insights and vision, and the ability to anticipate new

[Home](#)

[Strategy](#)

[Team](#)

[Research](#)

[Annual Meeting](#)

[LP Link](#)



[artificial intelligence](#)

---

[enterprise](#)

---

[bioinformatics](#)

---

[life sciences](#)

---

[blockchain](#)

---

[machine learning](#)

---

[consumer](#)

---

[novel therapeutics](#)

---

## why funds-of-funds?

PROVIDING INVESTORS WITH SIGNIFICANT INVESTMENT AND  
ECONOMIC BENEFITS

Venture capital funds-of-funds managers have a level of dedicated expertise and a depth and breadth of relationships applied to create diversified portfolios that may not be

[Home](#)[Strategy](#)[Team](#)[Research](#)[Annual Meeting](#)[LP Link](#)

LEARN MORE ABOUT OUR FUNDS-OF-FUNDS APPROACH

## the investment team

STRATEGICALLY INVESTING FOR OVER TWO DECADES

Prior to forming Spur in 2001, the Spur Directors invested through a variety of investment conditions back to the early 1990's and have developed a steady long-term orientation to the venture sector. In addition to the inaugural team, Spur has added two new investment partners. The venture capitalists with which the team has invested knows Spur as a stable, reliable, and value-added limited partner.

Among the team members' accomplishments are contributions to the advancement and evolution of terms and conditions, performance measurement, and research as well as authorship of several leading books and articles on private equity.

Spur's success in selecting funds that consistently outperform has been driven by the team's broad view of the investment universe, the diversity of its experience, longstanding relationships with fund managers, and reputations as thought leaders within early-stage investing.

LEARN MORE ABOUT THE SPUR  
CAPITAL TEAM

[Home](#)

[Strategy](#)

[Team](#)

[Research](#)

[Annual Meeting](#)

[LP Link](#)



capital

Financial, operational, and academic backgrounds provide a sound basis for making critical investment decisions

Together since 1998, predating the formation of Spur Capital Partners

Formed Spur in 2001 out of commitment to each other and a shared set of values and objectives

No turnover within the investment team since inception

#### SPUR DELIVERS STRONG PERFORMANCE BY:

Identifying and investing in high quality venture opportunities

Constructing and managing multi-vintage diversified portfolios

Ensuring the stability and continuity of our investment process and team

Providing exceptional service and support to limited partners

Offering the most balanced terms in the industry for our investors

[LEARN MORE ABOUT OUR INVESTMENT STRATEGY](#)

LP Link

Phone

Organization

SEND

2370 Nowata Place  
Bartlesville, OK 74006  
(918) 331-3800  
spur@spurcap.com

Twitter  
Disclaimer

Tweets by @SpurVentures



Spur Capital  
@SpurVentures

Spur IV and V Rare disease biotech Fulcrum  
Therapeutics files for an \$86 million IPO  
nasdaq.com/article/rare-d... via @ipotweet @Nasdaq